Insurance Red Tape Keeps Blistering Disease Patients From Lifesaving Biologics

For patients living with autoimmune blistering diseases such as pemphigus vulgaris and pemphigoid, the arrival of biologic therapies has been one of the most significant therapeutic advances in modern dermatology. These conditions, in which the immune system mistakenly attacks the proteins that hold skin cells together, produce painful blisters and erosions across the skin and mucous membranes. Left inadequately treated, they can be life-threatening. Yet a new research letter published in the Archives of Dermatological Research suggests that the greatest obstacle standing between many American patients and these advanced therapies is not the biology of their disease or the judgment of their physicians, but the administrative machinery of health insurance.

The study, led by Paige E. Adams, Elise K. Brunsgaard, Nikki Rezania, and senior author Kyle T. Amber of the Department of Dermatology at Rush University Medical Center in Chicago, together with Rebecca A. Strong and Marc Yale of the International Pemphigus and Pemphigoid Foundation, surveyed patients across the United States about their experiences seeking biologic therapy. The work is part of a broader research program by the same group examining how insurance requirements shape access to treatment in autoimmune bullous disease. An earlier single-center retrospective analysis by the team documented the impact of health insurance delays on biologic therapy access, and a companion survey of immunobullous experts in the United States has captured the perspective of the specialists who prescribe these drugs. The new patient-facing survey completes the picture by documenting what patients themselves endure.

Autoimmune blistering diseases are rare but devastating. In pemphigus vulgaris, autoantibodies target desmogleins, adhesion molecules of the desmosome, causing the superficial epidermis to shear apart in a process called acantholysis. Bullous pemphigoid, more common in older adults, involves autoantibodies against hemidesmosomal proteins such as BP180 and BP230, producing tense subepidermal blisters and intense pruritus. For decades, the backbone of treatment has been systemic corticosteroids, often combined with steroid-sparing immunosuppressants. Long-term steroid exposure, however, carries a heavy burden of morbidity, including diabetes, osteoporosis, infections, and cardiovascular risk, and mortality in these patients has historically been driven as much by treatment complications as by the disease itself.

Biologic therapies have changed that calculus. Rituximab, a monoclonal antibody that depletes CD20-positive B cells, demonstrated in the landmark Ritux 3 randomized trial published in The Lancet that first-line rituximab combined with short-term prednisone outperformed prednisone alone in pemphigus, achieving more complete remissions with less cumulative steroid exposure. Subsequent work, including studies comparing early and late rituximab initiation in pemphigus vulgaris, has reinforced the value of timely biologic treatment. More recently, targeted biologics have expanded the therapeutic arsenal for bullous pemphigoid as well. The clinical logic is straightforward: the earlier the autoimmune cascade is interrupted, the better the outcomes and the lower the cumulative toxicity from conventional immunosuppression.

But in the United States, the decision to prescribe a biologic is only the first step in a long process. Because these agents are expensive, insurers typically impose utilization management requirements before agreeing to cover them. Patients may face prior authorization, in which the prescribing physician must document that less expensive therapies have been tried and failed, or step therapy protocols that mandate a sequence of older drugs first. Appeals and peer-to-peer reviews can stretch the process over weeks or months. During that time, patients with active blistering disease may continue to form new lesions, suffer pain and infection risk, and accumulate steroid exposure that clinicians were specifically trying to avoid. The survey conducted by Adams and colleagues documents the human cost of these administrative delays from the patient’s perspective, revealing how frequently insurance-related barriers interrupt or postpone access to biologic therapy for this vulnerable population.

The significance of patient-reported data in this context is hard to overstate. Prior studies of utilization management have often relied on claims data or physician surveys, which capture the administrative timeline but not the lived experience of waiting. By partnering with the International Pemphigus and Pemphigoid Foundation, a patient advocacy organization based in Roseville, California, the research team was able to reach patients across the country who have navigated the insurance system while managing a rare, painful, and sometimes disfiguring disease. Strong and Yale, both employees of the foundation, brought direct insight into the concerns that patients raise most often, including the financial toxicity of high copayments, the confusion of navigating coverage denials, and the anxiety of watching their disease progress while paperwork is processed.

The findings arrive at a moment of intense national debate over prior authorization and utilization management. Professional societies across specialties have argued that these processes, originally designed to control costs, have proliferated to the point where they impose substantial burdens on both patients and physicians, with delays that can be clinically consequential. For rare diseases, the problem is compounded by unfamiliarity: insurers and their reviewers may have limited experience with pemphigus or pemphigoid, leading to requests for documentation or treatment sequences that do not reflect current clinical guidelines. When the evidence base supports early biologic intervention, as it does for pemphigus following the Ritux 3 trial, every month of delay represents a divergence between what the literature supports and what the patient actually receives.

The Rush University group’s research program illustrates how a single clinical question can be interrogated from multiple angles. Their retrospective single-center analysis quantified insurance delays in biologic therapy access using chart data. Their expert survey captured how immunobullous specialists perceive and manage these barriers in practice. The present patient survey adds the final dimension, grounding the policy discussion in the experiences of the people most affected. Together, these studies build a case that insurance-related barriers are not isolated anecdotes but a systematic feature of the American healthcare landscape as it intersects with rare autoimmune disease. The authors report no competing interests, and the work was supported in part by the Buntrock Fund for Bullous Pemphigoid Research, with corresponding author Kyle T. Amber also receiving research support from industry sources including Argenx, AstraZeneca, and Kabafusion.

What can be done? The research letter does not prescribe a single policy fix, but the implications are consistent with broader reform proposals gaining traction in American medicine. Streamlining prior authorization for therapies with strong guideline support, exempting rare diseases from step therapy requirements when first-line biologics are evidence-based, and creating expedited review pathways for conditions in which treatment delay causes direct harm are all measures that could shorten the gap between prescription and treatment. Electronic prior authorization, better transparency about coverage criteria, and specialty-specific clinical criteria developed with input from rare disease experts could reduce the friction that patients currently absorb. Patient advocacy organizations, which have become increasingly sophisticated in documenting these burdens, are likely to play a central role in pushing such reforms forward.

For the patients surveyed, the stakes are intimate and immediate: the difference between months of uncontrolled blistering and the remission that modern immunology can deliver. The study is a reminder that scientific progress, however dramatic, does not automatically translate into patient benefit. A monoclonal antibody that can silence a misguided immune attack on the skin’s structural proteins is of little use to someone whose insurance company has not yet approved it. As biologics continue to transform the treatment of pemphigus, pemphigoid, and other autoimmune diseases, the research from Rush University and the International Pemphigus and Pemphigoid Foundation makes clear that the next frontier in improving outcomes may lie not in the laboratory, but in the administrative systems that determine who gets access, and when.

Subject of Research: Insurance-related barriers to biologic therapy access for patients with autoimmune blistering diseases in the United States

Article Title: Insurance-related barriers to biologic therapy for autoimmune blistering diseases: a survey of patients in the United States

Article References: Adams, P. E., Brunsgaard, E. K., Rezania, N., Strong, R. A., Yale, M., & Amber, K. T. (2026). Insurance-related barriers to biologic therapy for autoimmune blistering diseases: a survey of patients in the United States. Archives of Dermatological Research, 318(1), Article 416. https://doi.org/10.1007/s00403-026-04788-0

Image Credits: AI Generated

DOI: 10.1007/s00403-026-04788-0

Keywords: autoimmune blistering diseases, pemphigus vulgaris, bullous pemphigoid, biologic therapy, rituximab, prior authorization, health insurance, step therapy, dermatology, rare disease, patient survey, healthcare access